Telix Pharmaceuticals (TLX) Competitors $16.50 +0.42 (+2.61%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$16.50 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock TLX vs. TEVA, SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, and BPMCShould you be buying Telix Pharmaceuticals stock or one of its competitors? The main competitors of Telix Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Telix Pharmaceuticals vs. Its Competitors Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines Teva Pharmaceutical Industries (NYSE:TEVA) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation. Is TEVA or TLX more profitable? Telix Pharmaceuticals has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -7.74%. Teva Pharmaceutical Industries' return on equity of 45.44% beat Telix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-7.74% 45.44% 6.95% Telix Pharmaceuticals N/A N/A N/A Do analysts prefer TEVA or TLX? Teva Pharmaceutical Industries presently has a consensus price target of $24.13, suggesting a potential upside of 41.33%. Telix Pharmaceuticals has a consensus price target of $22.00, suggesting a potential upside of 33.33%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Telix Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Telix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, TEVA or TLX? Telix Pharmaceuticals has lower revenue, but higher earnings than Teva Pharmaceutical Industries. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.18-$1.64B-$1.15-14.84Telix Pharmaceuticals$516.72M10.81$32.93MN/AN/A Does the media prefer TEVA or TLX? In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 16 mentions for Teva Pharmaceutical Industries and 3 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.80 beat Teva Pharmaceutical Industries' score of 0.74 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 6 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of TEVA or TLX? 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryTeva Pharmaceutical Industries beats Telix Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Get Telix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLX vs. The Competition Export to ExcelMetricTelix PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.44B$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E RatioN/A21.3126.1719.90Price / Sales10.81278.47413.55113.66Price / Cash140.8241.4736.1356.90Price / Book14.737.518.025.38Net Income$32.93M-$55.05M$3.15B$248.50M7 Day Performance0.61%2.07%1.48%2.06%1 Month Performance-2.77%4.84%3.66%4.86%1 Year PerformanceN/A5.37%34.68%20.24% Telix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLXTelix PharmaceuticalsN/A$16.50+2.6%$22.00+33.3%N/A$5.44B$516.72M0.00N/AGap DownHigh Trading VolumeTEVATeva Pharmaceutical Industries4.0821 of 5 stars$16.96+0.1%$24.44+44.1%+3.0%$19.44B$16.54B-14.7536,830SMMTSummit Therapeutics2.4753 of 5 stars$20.39-0.8%$35.09+72.1%+200.0%$15.27B$700K-59.97110Analyst ForecastITCIIntra-Cellular Therapies0.9141 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.8892 of 5 stars$20.68-2.3%$39.17+89.4%-17.9%$13.57B$3.12B11.752,682High Trading VolumeRDYDr. Reddy's Laboratories2.8228 of 5 stars$15.31+0.5%$16.95+10.7%-2.3%$12.71B$3.81B23.2027,811ASNDAscendis Pharma A/S3.5662 of 5 stars$175.78-0.6%$220.67+25.5%+27.0%$10.81B$393.54M-27.991,017Positive NewsVTRSViatris3.0627 of 5 stars$8.85-0.2%$10.40+17.5%-10.5%$10.41B$14.74B-2.7932,000QGENQiagen3.776 of 5 stars$46.72-0.1%$47.74+2.2%+22.8%$10.39B$1.98B117.145,765Dividend AnnouncementMRNAModerna4.3651 of 5 stars$25.67-0.9%$46.61+81.6%-74.1%$10.02B$3.24B-2.945,800Trending NewsOptions VolumeBPMCBlueprint Medicines1.5574 of 5 stars$128.40+0.2%$128.06-0.3%+16.2%$8.28B$508.82M-51.98640High Trading Volume Related Companies and Tools Related Companies TEVA Alternatives SMMT Alternatives ITCI Alternatives GMAB Alternatives RDY Alternatives ASND Alternatives VTRS Alternatives QGEN Alternatives MRNA Alternatives BPMC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
